Janney Montgomery Scott LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Janney Montgomery Scott LLC boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,490,986 shares of the company’s stock after acquiring an additional 90,661 shares during the period. Janney Montgomery Scott LLC owned about 0.13% of Teva Pharmaceutical Industries worth $32,861,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Diversify Advisory Services LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after purchasing an additional 496 shares during the last quarter. Diversify Wealth Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 22.9% in the fourth quarter. Diversify Wealth Management LLC now owns 42,759 shares of the company’s stock valued at $895,000 after acquiring an additional 7,969 shares during the period. Hennessy Advisors Inc. grew its position in shares of Teva Pharmaceutical Industries by 6.8% during the fourth quarter. Hennessy Advisors Inc. now owns 726,600 shares of the company’s stock worth $16,014,000 after acquiring an additional 46,300 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in Teva Pharmaceutical Industries by 19.8% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 371,583 shares of the company’s stock valued at $8,190,000 after purchasing an additional 61,467 shares during the last quarter. Finally, Contravisory Investment Management Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $221,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.2 %

Shares of TEVA opened at $21.75 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $11.48 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a 50-day moving average of $19.53 and a two-hundred day moving average of $18.32.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TEVA. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.63.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.